Clinical Trial Results:
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study GSK2857916 as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) – DREAMM 5
Summary
|
|
EudraCT number |
2019-001138-32 |
Trial protocol |
DE SE NL ES NO GR |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
27 Feb 2025
|
First version publication date |
10 Feb 2024
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
208887-Sub study1_Result summary_09Jan2024 208887-Sub study4_Result summary_11Feb2025 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.